Plasma protein therapies: Current and future perspectives

Best Practice and Research: Clinical Haematology

Volumn 19, Issue 1, 2006, Pages 243-258

  Farrugia, Albert ^a   Robert, Patrick ^b  

^a THERAPEUTIC GOODS ADMINISTRATION   (Australia)

^b The Marketing Research Bureau Inc   (United States)

Author keywords

Evidence; Manufacture; Plasma fractionation; Plasma protein therapies

Indexed keywords

ACTIVATED PROTEIN C; ALBUMIN; ALPHA 1 ANTITRYPSIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; BLOOD DERIVATIVE; FIBRINOGEN; IMMUNOGLOBULIN; PLASMA PROTEIN; PROTEIN C; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; TETANUS ANTIBODY; VON WILLEBRAND FACTOR;

BATTLE INJURY; BIOTECHNOLOGY; CHROMATOGRAPHY; CLINICAL MEDICINE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRYOPRECIPITATE; CRYOPRECIPITATION; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; EMPHYSEMA; EVIDENCE BASED PRACTICE; GOVERNMENT REGULATION; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; META ANALYSIS; PATHOPHYSIOLOGY; PLASMA TRANSFUSION; PRIORITY JOURNAL; PROCESS TECHNOLOGY; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; TREATMENT INDICATION;

BLOOD COMPONENT TRANSFUSION; BLOOD PROTEINS; HEMATOLOGIC DISEASES; HUMANS;

EID: 31044440526     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.01.002     Document Type: Review

References (45)

1. R.A. Good & E. Lorenz Historic aspects of intravenous immunoglobulin therapy Cancer 68 supplement 1994 1415-1421
2. T. Addis The pathogenesis of hereditary haemophilia J Pathol Bacteriol 15 1911 427-452
3. M. Blombach Purification of antihaemophilic globulin Arkiv fur Kemi 12 1958 387-396
4. E.J. Cohn L.E. Strong W.L. Hughes et al. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids J Am Chem Soc 68 1946 459-475
5. D.B. Kendrick Byproducts of plasma fractionation in: Blood Program in World War II 2004 [Online. Available at: http://history.amedd.army.mil/ booksdocs/wwii/blood/chapter13.htm, accessed 20 November 2004]
6. J.G. Poole & A.E. Shannon Production of antihaemophilic globulin in a closed bag system NEJM 273 1965 1443
7. Remigy E. Essais de traitement par plasma cryoconcentre. University of Nancy, Academic thesis.
8. W.P. Webster H.R. Roberts G.M. Thelin et al. Clinical use of a new glycine-precipitated antihemophilic fraction Am J Med Sci; 250 1965 643-651
9. A. Farrugia Manufacturing standards for plasma for fractionation-scientific relevance and regulatory requirements Food and Drug Administration Public Workshop on Plasma Standards 31 August 2004 [Online. Available at: http://www.fda.gov/cber/minutes/ plsmstd083104t.pdf, accessed 20 November 2004]
10. S.A. Larsson Life expectancy of Swedish haemophiliacs, 1831-1980 Br J Haematol 59 1985 593-602
11. Farrugia A, Poulis P. Intravenous immunoglobulin. Regulatory Perspectives on Use and Supply Trans Med 2001; 11: 63-74.
12. A. Farrugia C.S. Manno & B.L. Evatt Emerging and receding risks of therapeutic regimens for haemophilia Haemophilia 10 supplement 4 2004 47-54
13. S.M. Opal Therapeutic rationale for antithrombin III in sepsis Crit Care Med 28 9 2000 S34-S37
14. M. Haley X. Cui P.C. Minneci et al. Recombinant human activated protein C in sepsis: Assessing its clinical use Am J Med Sci 328 2004 215-219
15. Kendrick DB. The Blood, Plasma, and Related Programs in the Korean War in Blood Program in World War II [Online. Available at: http://history.amedd.army.mil/booksdocs/wwii/blood/ chapter20.htm#table42].
16. Krever H. Report of the Krever Commission of Inquiry into the Blood System in Canada; 1996 [Online. Available at: http://www.hc-sc.gc.ca/english/krever/k_wp_e.html].
17. Loveton LB, Sox HC, Stoto MA (eds.), HIV and the Blood Supply: An Analysis of Crisis Decision Making. Washington DC: National Academy Press; 1995.
18. J.M. Bult Industry perspectives on the global blood products market-supply, access and affordability Haemophilia 10 supplement 3 2004 26S-28S
19. Ralston D. Warning letter to CEO of Aventis behring, 2001 [Online. Available at: http://www.fda.gov/foi/warning_Letter/g4240d.pdf
20. B.R. Jackson M.P. Busch S.L. Stramer & J.P. AuBuchon The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Transfusion 43 6 2003 721-729
21. Dorner F, Eibl J, Zerlauth G. A quality-assured gene amplification assay system (PCR) for use on an industrial-scale - a proposal for validation. Presented at the German Thrombosis and Haemostasis Society Interlaken; 14-17.2.1996.
22. Scott D. TSEAC; Oct. 2004 [Online. Available at: http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4075S1_04.ppt].
23. de Oliveira GG. Brazilian program for self-sufficiency in blood products, 2002 [Online. Available at: http://www.who.int/medicines/ library/qsm/icdra02/ppt/Plasma_Fraction.ppt].
24. Wendel S. A Brazilian perspective on plasma product self sufficiency. Presented to WFH Bangkok.
25. T.R. Kreil A. Berting O. Kistner & J. Kindermann West Nile virus and the safety of plasma derivatives: Verification of high safety margins, and the validity of predictions based on model virus data Transfusion 43 2003 1023-1028
26. J.W. Ironside & M.W. Head Variant Creutzfeldt-Jakob disease: Risk of transmission by blood and blood products Haemophilia 10 supplement 4 2004 64-69
27. Plasma Protein Therapeutics Association. Emerging infectious diseases roundtable Brussels. Submitted for publication.
28. J. Gitschier W.I. Wood T.M. Goralka et al. Characterization of the human factor VIII gene Nature 312 1984 326-330
29. G.C. White 2nd C.W. McMillan H.S. Kingdon et al. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia N Engl J Med 320 1989 166-170
30. M.V. Ragni A. Shapiro G.C. White et al. Use of recombinant FIX in three patients with haemophilia B undergoing surgery Blood 86 supplement 1 1995 [194a abst no. 762]
31. J. Bichler M.O. Spycher H.P. Amstutz et al. Pharmacokinetics and safety of recombinant anti-RhD in healthy RhD-negative male volunteers Transfus Med 14 2 2004 165-171
32. R.F. Robinson & M.C. Nahata Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection Am J Health Syst Pharm 57 7 2000 699
33. Aventis Behring. Aventis Behring Announces Successful Results for First Recombinant Albumin Phase I Clinical Trial [Online. Available at: http://www.zlbbehring.com/zb/n35241pr34290/AventisBehringAnnoun.htm].
34. S.S. Waikar G.M. Chertow S.S. Waikar & G.M. Chertow Crystalloids versus colloids for resuscitation in shock Curr Opin Nephrol Hypertens 9 5 2000 501-504
35. Cochrane Injuries Group Albumin Reviewers Human albumin administration in critically ill patients: Systematic review of randomised controlled trials BMJ 317 1998 235-240
36. The SAFE Study Investigators A comparison of albumin and saline for fluid resuscitation in the intensive care unit N Engl J Med 350 2004 2247-2256
37. M.D. Deborah Cook Is albumin safe? N Engl J Med 350 2004 2294-2296
38. C.M. Miles P. Brown H. Chapel et al. Intravenous immunoglobulin in neurological disease: A specialist review J Neurol Neurosurg Psychiatry 72 2002 440-448
39. D. Karussis & O. Abramsky Is the routine use of intravenous immunoglobulin treatment in neurologic disorders justified? No Arch Neurol. 56 1999 1028-1032
40. Australian Health Ministers Advisory Council Review of the Use and Supply of Intravenous Immunoglobulins in Australia 2000 [Online. Available at: http://www.nba.gov.au/pdf/ivig.pdf]
41. C. Cordonnier S. Chevret M. Legrand et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? Ann Intern Med 139 2003 8-18
42. S. Nagpal T. Benstead K. Shumak et al. Treatment of Guillain-Barre syndrome: A cost-effectiveness analysis J Clin Apheresis 14 1999 107-113
43. A. Srivastava M. Chandy & G.D. Sunderaj Low dose intermittent factor replacement for post-operative haemostasis in haemophilia Haemophilia 4 1998 799-801
44. G. Auerswald T. Spranger & H.H. Brackmann The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients Haematologica 88 2003
45. H.W. Eijkhout J.W.M. van der Meer G.M. Cees et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: A randomized, double-blind, multicenter crossover trial Ann Intern Med 165 2001 174